Meito Sangyo Kabushiki Kaisha

Other

Meito Sangyo Co., Ltd.

Kao Corporation

Shigeaki Kato

Yoshitaka Kokusho

Haruo Machida

Akira Tsunoda

Mitsuo Aoki

Hiroyuki Kobayashi

Tomihiro Kurosaki

Takashi Imamura

Katsumi Kita

Yasuo Ishii

Mitsuharu Masuda

Haruya Kato

Hideki Kobatake

Yuuki Hirata

Noriko Inoue

Takashi Itoh

Yoshiko Chikawa

Kazunori Harada

Kazushi Tahara

Akira Iwami

Akira Obi

Hisato Tanaka

Hiroyuki Yamaguchi

Taro Suga

The present invention provides an improved type protease which comprises an amino acid sequence that is at least 75% identical to SEQ ID NO:3, said improved type protease has at least one mutation selected from the group consisting of: (A) replacement of glutamine corresponding to glutamine at position 265 in SEQ ID NO: 3 with an acidic amino acid; and (B) replacement of glutamine at position 266 in SEQ ID NO: 3 with an acidic amino acid, and wherein said improved type protease has milk-clotting activity.

Milk-clotting protease derived from a microorganism

According to the present invention, as processing apparatus drive starts, the operating state of software used to drive the processing apparatus is monitored in real time to diagnose whether or not an abnormality has occurred (S). If it is judged through the diagnosis performed in Sthat no abnormality has occurred, the workpiece processing is allowed to continue uninterrupted and then a decision is made as to whether or not the workpiece processing has been completed (S). If the processing has been completed, the processing apparatus is stopped (S). If, on the other hand, it is judged through the diagnosis performed in Sthat an abnormality has occurred, a log of the diagnosis item with regard to which the abnormality has occurred is recorded (S). The processing apparatus is then stopped (S).

Methods of self-diagnosing software for driving processing apparatus

The present invention relates to dextran whose boron content is reduced to a value less than 0.30 &mgr;g/g (dry basis) calculated on the basis of boron atom, a process for producing the same, and dextran with which a container is filled in a solution state. Dextran of the present invention is obtained by treating a boron-containing dextran with a lower alcohol, and said dextran has such a characteristic that deposition is inhibited or the deposition rate is drastically reduced when using it in the form of a solution. Therefore, an isotonic sodium chloride solution of said dextran is suitably used as substitute plasma or external perfusate in an operation.

Process for producing dextran reduced in boron content

A novel monophosphate and a novel diphosphate prepared by a phosphatidyl transfer reaction of a phospholipid and an alcohol in the presence of phospholipase D are disclosed. The phosphates can independently or together form small and stable liposomes which can include active components therein. Cosmetic compositions comprising these phosphates or liposomes penetrate well into the hair and the skin, and exhibit long-lasting excellent moisture-retaining, beauty, skin-activation effects.

Phosphate, liposome comprising the phosphate as membrane constituent,

A process for producing a primary or secondary alcohol derivative of a phosopholipid which comprises reacting the phospholipid with a primary or secondary alcohol in the presence of phospholipase DM.

Production of primary or secondary alcohol derivatives of phospholipids

A process for producing a sphingophospholipid derivative comprising reacting a sphingophospholipid with a specified compound having an alcoholic hydroxyl group selected from the group consisting of specified primary alcohol compounds, specified secondary alcohol compounds and specified saccharides or their phenol glycosides in the presence of phospholipase DM.

Enzymatic production of sphingophospholipid derivatives

A process for producing a saccharide derivative of a phospholipid, which comprises reacting a phospholipid with a monosaccharide having 5 to 7 carbon atoms, at least one primary alcohol group and at least three hydroxyl groups in total including the OH of the primary alcohol group or a disaccharide thereof, said saccharide being optionally substituted by a group selected from the class consisting of amino and acetylamino groups, or a phenol glycoside of said saccharide in the presence of phospholipase DM. The phospholipid-saccharide derivatives are useful as a liposome-forming substrate, or as an emulsifier for cosmetics, such as cream and lotion, fat solutions for transfusion and agricultural chemicals, such as pesticides and herbicides.

Enzymatic production of phospholipid-saccharide derivatives

Growing community of inventors

Hachioji, Japan

Shigeaki Kato